Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption

Abstract

Naringenin can inhibit human osteoclastogenesis and osteoclastic bone resorption. It thus holds promise as a therapeutic or preventive agent for bone-related diseases such as periodontitis.